Related Experiment Videos
Acute promyelocytic leukemia: a case-based review
Vikas Gupta1, Daniel Tabak, Armand Keating
1Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada; M5G 2M9. vikas.gupta@uhn.on.ca
Hematology (Amsterdam, Netherlands)
|May 15, 2003
Summary
All-trans retinoic acid (ATRA) has transformed acute promyelocytic leukemia (APL) from a fatal diagnosis to a curable condition. This review covers recent advancements in APL management, including maintenance therapy and relapse treatment.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) was historically fatal.
- Retinoid therapy, specifically all-trans retinoic acid (ATRA), has revolutionized APL treatment.
Observation:
- ATRA has dramatically improved the prognosis of APL.
- This review synthesizes clinical and scientific data on APL management.
Findings:
- Recent progress in APL management is highlighted.
- The review addresses maintenance therapy, prognostic factors for relapse, and treatment strategies for relapsed APL.
Implications:
- Evidence-based decisions in APL management are crucial.
- Continued research into retinoid therapy and APL treatment is essential for improving patient outcomes.